Convalescent Plasma for Covid-19-Induced ARDS in Mechanically Ventilated Patients
Copyright © 2023 Massachusetts Medical Society..
BACKGROUND: Passive immunization with plasma collected from convalescent patients has been regularly used to treat coronavirus disease 2019 (Covid-19). Minimal data are available regarding the use of convalescent plasma in patients with Covid-19-induced acute respiratory distress syndrome (ARDS).
METHODS: In this open-label trial, we randomly assigned adult patients with Covid-19-induced ARDS who had been receiving invasive mechanical ventilation for less than 5 days in a 1:1 ratio to receive either convalescent plasma with a neutralizing antibody titer of at least 1:320 or standard care alone. Randomization was stratified according to the time from tracheal intubation to inclusion. The primary outcome was death by day 28.
RESULTS: A total of 475 patients underwent randomization from September 2020 through March 2022. Overall, 237 patients were assigned to receive convalescent plasma and 238 to receive standard care. Owing to a shortage of convalescent plasma, a neutralizing antibody titer of 1:160 was administered to 17.7% of the patients in the convalescent-plasma group. Glucocorticoids were administered to 466 patients (98.1%). At day 28, mortality was 35.4% in the convalescent-plasma group and 45.0% in the standard-care group (P = 0.03). In a prespecified analysis, this effect was observed mainly in patients who underwent randomization 48 hours or less after the initiation of invasive mechanical ventilation. Serious adverse events did not differ substantially between the two groups.
CONCLUSIONS: The administration of plasma collected from convalescent donors with a neutralizing antibody titer of at least 1:160 to patients with Covid-19-induced ARDS within 5 days after the initiation of invasive mechanical ventilation significantly reduced mortality at day 28. This effect was mainly observed in patients who underwent randomization 48 hours or less after ventilation initiation. (Funded by the Belgian Health Care Knowledge Center; ClinicalTrials.gov number, NCT04558476.).
| Errataetall: |
CommentIn: N Engl J Med. 2024 Jan 25;390(4):384-385. - PMID 38265659 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:389 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 389(2023), 17 vom: 26. Okt., Seite 1590-1600 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 30.10.2023 Date Revised 12.03.2024 published: Print-Electronic ClinicalTrials.gov: NCT04558476 CommentIn: N Engl J Med. 2024 Jan 25;390(4):384-385. - PMID 38265659 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2209502 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363811753 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363811753 | ||
| 003 | DE-627 | ||
| 005 | 20240312233317.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2209502 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM363811753 | ||
| 035 | |a (NLM)37889107 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Misset, Benoît |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Convalescent Plasma for Covid-19-Induced ARDS in Mechanically Ventilated Patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.10.2023 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04558476 | ||
| 500 | |a CommentIn: N Engl J Med. 2024 Jan 25;390(4):384-385. - PMID 38265659 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: Passive immunization with plasma collected from convalescent patients has been regularly used to treat coronavirus disease 2019 (Covid-19). Minimal data are available regarding the use of convalescent plasma in patients with Covid-19-induced acute respiratory distress syndrome (ARDS) | ||
| 520 | |a METHODS: In this open-label trial, we randomly assigned adult patients with Covid-19-induced ARDS who had been receiving invasive mechanical ventilation for less than 5 days in a 1:1 ratio to receive either convalescent plasma with a neutralizing antibody titer of at least 1:320 or standard care alone. Randomization was stratified according to the time from tracheal intubation to inclusion. The primary outcome was death by day 28 | ||
| 520 | |a RESULTS: A total of 475 patients underwent randomization from September 2020 through March 2022. Overall, 237 patients were assigned to receive convalescent plasma and 238 to receive standard care. Owing to a shortage of convalescent plasma, a neutralizing antibody titer of 1:160 was administered to 17.7% of the patients in the convalescent-plasma group. Glucocorticoids were administered to 466 patients (98.1%). At day 28, mortality was 35.4% in the convalescent-plasma group and 45.0% in the standard-care group (P = 0.03). In a prespecified analysis, this effect was observed mainly in patients who underwent randomization 48 hours or less after the initiation of invasive mechanical ventilation. Serious adverse events did not differ substantially between the two groups | ||
| 520 | |a CONCLUSIONS: The administration of plasma collected from convalescent donors with a neutralizing antibody titer of at least 1:160 to patients with Covid-19-induced ARDS within 5 days after the initiation of invasive mechanical ventilation significantly reduced mortality at day 28. This effect was mainly observed in patients who underwent randomization 48 hours or less after ventilation initiation. (Funded by the Belgian Health Care Knowledge Center; ClinicalTrials.gov number, NCT04558476.) | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 700 | 1 | |a Piagnerelli, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Hoste, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Dardenne, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Grimaldi, David |e verfasserin |4 aut | |
| 700 | 1 | |a Michaux, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a De Waele, Elisabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Dumoulin, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Jorens, Philippe G |e verfasserin |4 aut | |
| 700 | 1 | |a van der Hauwaert, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Vallot, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Lamote, Stoffel |e verfasserin |4 aut | |
| 700 | 1 | |a Swinnen, Walter |e verfasserin |4 aut | |
| 700 | 1 | |a De Schryver, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Fraipont, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a de Mey, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Dauby, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Layios, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Mesland, Jean-Baptiste |e verfasserin |4 aut | |
| 700 | 1 | |a Meyfroidt, Geert |e verfasserin |4 aut | |
| 700 | 1 | |a Moutschen, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Compernolle, Veerle |e verfasserin |4 aut | |
| 700 | 1 | |a Gothot, André |e verfasserin |4 aut | |
| 700 | 1 | |a Desmecht, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Taveira da Silva Pereira, Maria I |e verfasserin |4 aut | |
| 700 | 1 | |a Garigliany, Mutien |e verfasserin |4 aut | |
| 700 | 1 | |a Najdovski, Tome |e verfasserin |4 aut | |
| 700 | 1 | |a Bertrand, Axelle |e verfasserin |4 aut | |
| 700 | 1 | |a Donneau, Anne-Françoise |e verfasserin |4 aut | |
| 700 | 1 | |a Laterre, Pierre-François |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 389(2023), 17 vom: 26. Okt., Seite 1590-1600 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:389 |g year:2023 |g number:17 |g day:26 |g month:10 |g pages:1590-1600 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2209502 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 389 |j 2023 |e 17 |b 26 |c 10 |h 1590-1600 | ||